Acquisition history Recent ownership shift via Novartis acquisition in 2016 and subsequent exposure to Selexys technology presents an opportunity to re-engage legacy assets or explore partnerships around acquired IP and platforms for new drug development.

Small team, niche focus With 2-10 employees, the company operates as a small, specialized entity likely open to strategic collaborations, licensing deals, or white-labeling opportunities to accelerate development timelines.

Technology backbone Established use of cloud and web technologies (AWS, Google Cloud, OpenResty, Nginx, React) suggests receptiveness to tech-enabled partnerships, data collaborations, and scalable digital solution alignments for R&D or manufacturing processes.

Financial signals Revenue range of zero to one million indicates early-stage or asset-based value; potential fit for licensing, milestone-based partnerships, or co-development arrangements with larger pharma or biotech firms.

Strategic fit Historical connection to Novartis and a portfolio likely aimed at innovative therapeutics positions the company as a potential target for acquisitive partnerships, research collaborations, or joint ventures with major industry players seeking novel technologies.